MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Lantheus Holdings Inc

Fermé

SecteurSoins de santé

80.15 2.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

79.12

Max

80.59

Chiffres clés

By Trading Economics

Revenu

85M

73M

Ventes

-18M

373M

P/E

Moyenne du Secteur

23.322

40.527

BPA

1.53

Marge bénéficiaire

19.569

Employés

808

EBITDA

93M

115M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+51.26% upside

Dividendes

By Dow Jones

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.8B

5.7B

Ouverture précédente

77.77

Clôture précédente

80.15

Sentiment de l'Actualité

By Acuity

40%

60%

126 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Lantheus Holdings Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2025, 23:45 UTC

Acquisitions, Fusions, Rachats

Orix Corp. USA to Buy Majority Stake in Hilco Global >8591.TO

3 juil. 2025, 23:42 UTC

Market Talk

Gold Edges Higher Amid U.S. Fiscal-Deficit Concerns -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Nikkei May Rise After Solid U.S. Jobs Data -- Market Talk

3 juil. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 23:15 UTC

Market Talk
Acquisitions, Fusions, Rachats

Beach Energy Could Smooth Path to Santos Takeover Approval -- Market Talk

3 juil. 2025, 22:59 UTC

Market Talk

Uranium Market About to Enter Lull -- Market Talk

3 juil. 2025, 22:58 UTC

Market Talk

Value Emerging in Diversified Miners Despite Headwinds -- Market Talk

3 juil. 2025, 22:47 UTC

Market Talk

Australian Household Spending Numbers Key Ahead of RBA Meeting -- Market Talk

3 juil. 2025, 22:21 UTC

Résultats

This Summer's Big TV Hit Brings Back Soap Opera Memories -- Barrons.com

3 juil. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

KKR Seen As Benefiting From Stabilizing Markets -- Market Talk

3 juil. 2025, 20:41 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 19:28 UTC

Market Talk

Oil Gives Back Some Gains With OPEC+ in View -- Market Talk

3 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Retreats Ahead of Long Weekend -- Market Talk

3 juil. 2025, 18:34 UTC

Market Talk

Gold Has Winning Week, But Down Day -- Market Talk

3 juil. 2025, 18:18 UTC

Market Talk

Anticipation for Trump Address Gives Grain Traders Optimism -- Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Global Equities Roundup: Market Talk

3 juil. 2025, 18:06 UTC

Market Talk

Brazilian Stocks, Bonds Expected to Benefit From Benign Macro Trends -- Market Talk

3 juil. 2025, 17:27 UTC

Market Talk

U.S. Oil Rig Count Continues to Slide -- Market Talk

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious -2-

3 juil. 2025, 16:55 UTC

Résultats

Travel Stocks Could Offer Investors a Glorious Trip, This Analyst Says -- Barrons.com

3 juil. 2025, 16:20 UTC

Market Talk

Correction to Health Care Roundup: Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Oil Futures Lose Ground in Choppy Pre-Holiday Trade -- Market Talk

3 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juil. 2025, 16:05 UTC

Market Talk

Gold Futures Fall Following Jobs Report -- Market Talk

3 juil. 2025, 15:47 UTC

Résultats

Honeywell Stock Is on a Roll. It Looks Ready to Break Out. -- Barrons.com

3 juil. 2025, 15:36 UTC

Résultats
Acquisitions, Fusions, Rachats

Why It's Time to Buy This Rocks and Cement Spinoff Stock You've Probably Never Heard Of -- Barrons.com

Comparaison

Variation de prix

Lantheus Holdings Inc prévision

Objectif de Prix

By TipRanks

51.26% hausse

Prévisions sur 12 Mois

Moyen 120.43 USD  51.26%

Haut 137 USD

Bas 109 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

79.24 / 103.64Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

126 / 375Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.